Role of biosimilar introduction on insulin glargine prices : a retrospective analysis in 28 European countries

Article Article scientifique Article Role of biosimilar introduction on insulin glargine prices : a retrospective analysis in 28 European countries eng 2025-01-30 2025-01 author Morolla Davide 0009-0005-6785-9674 author Beran David Henri 0000-0001-7229-3920 767231 Département de santé et médecine communautaire (MECOM) author Ewen Margaret author Raviglione Mario 0000-0002-9331-2067 author Von Schoen - Angerer Tido 0000-0003-3601-7480 827613 e090484 10.1136/bmjopen-2024-090484 39890142 2044-6055 PMC11795371 https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2024-090484 Objective : Quantify insulin glargine prices following the market introduction of biosimilars. Examine price levels and price changes for originator and biosimilars, by country. Methods : Retrospective quantitative analysis using insulin glargine pricing data, both of the originator product and its biosimilars. Segmented regression analysis using a dual-model approach: pooled and country-specific. Setting : 28 European countries using data from the European Medicine Price Database for the period 2013-2023. Main outcome measures : Price variations between countries were analysed to assess trends and correlations before and after biosimilar market entry. Results : In the 28 countries studied, cost of insulin glargine underwent a median 21.6% decrease overall in the last decade (p<0.001). In 2022, the median price was €9.0 for the originator (first to market) Lantus (IQR €8.1–€10.4), €8.9 for the biosimilar Abasaglar (IQR €7.6–€10.1) and €7.0 for the biosimilar Semglee (median €7.0; IQR €6.8–€7.5). The originator price was higher than biosimilars (p=0.009). Biosimilar market entry was associated with an overall significant price reduction of the originator, both immediately after entry (p<0.001) and in the long-term postentry (p<0.001). No significant correlation was observed between the price of insulin and the countries’ economic indicators. Conclusion : This is the first study to show the price trend of insulin glargine and its correlation with the introduction of biosimilars, in Europe. A significant price reduction of the originator was observed after biosimilars entered the market. The median cost of biosimilars was lower than the originator, although with substantial differences between individual countries and producers. Health economics Health policy Public health Dewey 613 Dewey 618 The Leona M. and Harry B. Helmsley Charitable Trust 230206660 64 Département de santé et médecine communautaires 22A 58 Département de pédiatrie, gynécologie et obstétrique 223 false BMJ open 15 1 5cfbd9bb-c401-47a5-b8ea-1d210df51bf3 Article (Published version) Public Role_of_biosimilar_introduction_on_.pdf 1342925 application/pdf CC BY-NC-4.0 678a90c05c904a70f05cf7f285935afb51c4733d2fa20b585abf85cddcaeaa1d openAccess Faculté de médecine / Section de médecine clinique / Département de santé et médecine communautaires Faculté de médecine / Section de médecine clinique / Département de pédiatrie, gynécologie et obstétrique

Title	Published in	Access level	OA Policy	Year	Views	Downloads

Role of biosimilar introduction on insulin glargine prices : a retrospective analysis in 28 European countries	BMJ open			2025	44	72

Archive ouverte UNIGE

Von Schoen - Angerer, Tido